Positive results from MB07803 in poorly controlled T2DM will be presented in June poster session at ADA. Good to see something positive and in Ph2 from this company. Even after their head count reduction in Jan [still have about 50 on the payroll], they probably run out of money between end of July and middle of October. Are the results good enough to partner and bring in cash or do they need to sell shares at this low a price?
Wonder what progress 7811 is making in its Ph2 for hyperlidideermia?
graham
--
Metabasis Therapeutics Announces Late-Breaking Abstract on MB07803 Trial Results Accepted for Presentation at the American Diabetes Association Meeting
On Wednesday May 6, 2009, 8:00 am EDT
SAN DIEGO--(BUSINESS WIRE)--Metabasis Therapeutics, Inc. (Nasdaq: MBRX - News) announced today that its late-breaking abstract has been accepted for presentation at the American Diabetes Association’s 69th Scientific Sessions in New Orleans, LA (June 5-9, 2009). The abstract, entitled “Pronounced Glucose Reduction In Poorly Controlled T2DM with MB07803, a Novel Fructose-1,6-bisphosphatase Inhibitor (FBPaseI) with Reduced Potential for Acid-Base Disturbances vs the 1st Generation FBPaseI CS-917” will be presented in poster format in the Clinical Therapeutics/New Technology-Pharmacologic Treatment of Diabetes or its Complications category.
The poster presentation will disclose results from a 14-day, single-center, randomized, double-blind, PBO-controlled, ascending multi-dose trial in forty-two patients with poorly-controlled type 2 diabetes mellitus. MB07803 is Metabasis’ second-generation product candidate from a new class of drugs that the Company discovered internally for the treatment of type 2 diabetes. MB07803 is designed to reduce glucose production in the liver by inhibiting the enzyme fructose-1,6-bisphosphatase (FBPase). Excess glucose production is a major contributor to the elevated glucose levels found in patients with type 2 diabetes. Inhibitors of FBPase are expected to fulfill an unmet medical need because the majority of current antidiabetic medications act primarily on insulin resistance or impaired insulin secretion and do not effectively or directly reduce endogenous glucose production. Prior to this trial, MB07803 had been evaluated in five Phase 1 trials in healthy volunteers and in a Phase 2a initial proof-of-concept trial in 105 patients with type 2 diabetes.
The poster has been assigned presentation number 11-LB and is available for viewing throughout the duration of the conference. Barry Gumbiner, M.D., Metabasis’ chief medical officer and vice president of clinical development will be available to answer questions on Saturday, June 6 from 11:30 am to 1:30 pm and during the evening Poster Session Reception for this category.
“Acceptance of our late-breaking abstract by the American Diabetes Association review committee provides an opportunity for us to present the results from our recent clinical trial on MB07803 at one of the world’s most well-attended and important conferences on diabetes,” stated Mark Erion, Ph.D., president, chief executive officer and chief scientific officer. “Based on our studies to date, we believe that MB07803 represents a promising new class of oral drugs for treating patients with type 2 diabetes.” |
